Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer.
Saved in:
| Title: | Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer. |
|---|---|
| Authors: | Bordry N; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Addeo A; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Jaksic C; CRC& Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, Geneva, Switzerland., Dutoit V; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Roux-Lombard P; Immunology and Allergology Laboratory, Geneva University Hospital, University of Geneva, 1205 Geneva, Switzerland., Shah DP; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA., Shah PK; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA., Gayet-Ageron A; CRC& Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospital, Geneva, Switzerland., Friedlaender A; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland.; Oncology Department, University Hospital of Geneva, Switzerland, Clinique Générale Beaulieu, Geneva, Switzerland., Bugeia S; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Gutknecht G; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Battagin A; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Di Marco M; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Simand PF; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Labidi-Galy I; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Fertani S; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Sandoval J; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Dietrich PY; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland., Mach N; Department of Oncology, Geneva University Hospital, University of Geneva and Swiss Cancer Center Leman, Rue Perret-Gentil 4, 1205 Geneva, Switzerland. |
| Source: | IScience [iScience] 2021 Dec 24; Vol. 25 (1), pp. 103699. Date of Electronic Publication: 2021 Dec 24 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
